These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19669066)

  • 1. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
    Lindner LM; Marasciulo AC; Farias MR; Grohs GE
    Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G; Heeg B; van Hout BA; Mehnert A
    Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M; Okamoto MP
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S; O'Donnell O
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].
    Quitian Reyes H; Arciniegas Barrera JA; Bohórquez Peñaranda A; Gómez Restrepo C
    Rev Colomb Psiquiatr; 2016; 45(2):67-74. PubMed ID: 27132755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
    Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
    J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
    Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
    J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of olanzapine and risperidone in Norway.
    Kim K; Aas E
    J Ment Health Policy Econ; 2011 Sep; 14(3):125-35. PubMed ID: 22116170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.